1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association between non-cystic fibrosis bronchiectasis and the risk of incident dementia: A nationwide cohort study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Chronic lung diseases, such as chronic obstructive pulmonary disease or asthma, are associated with an increased risk of dementia. However, few data are available regarding the risk of dementia in individuals with bronchiectasis.

          Objectives

          To explore the association between bronchiectasis and the risk of incident dementia using a longitudinal population-based cohort.

          Methods

          A total of 4,068,560 adults older than 50 years without previous dementia were enrolled from the Korean National Health Insurance Service database in 2009. They were followed up until the date of the diagnosis of dementia or December 31, 2020. The study exposure was the diagnosis of bronchiectasis, and the primary outcome was incident dementia comprising Alzheimer’s disease and vascular dementia.

          Results

          During the median follow-up duration of 9.3 years, the incidence of all-cause dementia was 1.6-fold higher in individuals with bronchiectasis than in those without bronchiectasis (15.0 vs. 9.3/1000 person-years, p < .001). In the multivariable Cox regression analysis, the risk of all dementia was significantly higher in individuals with bronchiectasis than in those without bronchiectasis (adjusted hazard ratio [aHR] 1.09, 95% confidence interval [CI] 1.04–1.14). In a subgroup analysis by dementia type, individuals with bronchiectasis had an increased risk of Alzheimer’s disease compared to those without bronchiectasis (aHR 1.07, 95% CI 1.01–1.12); the risk of vascular dementia did not significantly differ between the two groups (aHR 1.05, 95% CI 0.90–1.21).

          Conclusion

          Bronchiectasis was associated with an increased risk of dementia, especially Alzheimer’s disease.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: found

          Dementia prevention, intervention, and care

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

            Background Given the projected trends in population ageing and population growth, the number of people with dementia is expected to increase. In addition, strong evidence has emerged supporting the importance of potentially modifiable risk factors for dementia. Characterising the distribution and magnitude of anticipated growth is crucial for public health planning and resource prioritisation. This study aimed to improve on previous forecasts of dementia prevalence by producing country-level estimates and incorporating information on selected risk factors. Methods We forecasted the prevalence of dementia attributable to the three dementia risk factors included in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 (high body-mass index, high fasting plasma glucose, and smoking) from 2019 to 2050, using relative risks and forecasted risk factor prevalence to predict GBD risk-attributable prevalence in 2050 globally and by world region and country. Using linear regression models with education included as an additional predictor, we then forecasted the prevalence of dementia not attributable to GBD risks. To assess the relative contribution of future trends in GBD risk factors, education, population growth, and population ageing, we did a decomposition analysis. Findings We estimated that the number of people with dementia would increase from 57·4 (95% uncertainty interval 50·4–65·1) million cases globally in 2019 to 152·8 (130·8–175·9) million cases in 2050. Despite large increases in the projected number of people living with dementia, age-standardised both-sex prevalence remained stable between 2019 and 2050 (global percentage change of 0·1% [–7·5 to 10·8]). We estimated that there were more women with dementia than men with dementia globally in 2019 (female-to-male ratio of 1·69 [1·64–1·73]), and we expect this pattern to continue to 2050 (female-to-male ratio of 1·67 [1·52–1·85]). There was geographical heterogeneity in the projected increases across countries and regions, with the smallest percentage changes in the number of projected dementia cases in high-income Asia Pacific (53% [41–67]) and western Europe (74% [58–90]), and the largest in north Africa and the Middle East (367% [329–403]) and eastern sub-Saharan Africa (357% [323–395]). Projected increases in cases could largely be attributed to population growth and population ageing, although their relative importance varied by world region, with population growth contributing most to the increases in sub-Saharan Africa and population ageing contributing most to the increases in east Asia. Interpretation Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform national planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia. Funding Bill & Melinda Gates Foundation and Gates Ventures.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diagnosis and Management of Dementia: Review

              Worldwide, 47 million people live with dementia and, by 2050, the number is expected to increase to 131 million. Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function. In the US, Alzheimer’s disease (AD) affects 5.8 million people. However, dementia is commonly associated with more than one neuropathology, usually AD with cerebrovascular pathology. Diagnosing dementia requires a history evaluating for cognitive decline and impairment in daily activities, with corroboration from a close friend or family member, in addition to a moderately extended mental status examination by a clinician to delineate impairments in memory, language, attention, visuospatial cognition such as spatial orientation, executive function, and mood. Brief cognitive impairment screening questionnaires can assist in initiating and organizing the cognitive assessment. However, if the assessment is inconclusive (e.g., symptoms present, but normal examination), neuropsychological testing can help with a diagnosis. Physical examination may help identify the etiology of dementia. For example, focal neurologic abnormalities suggest stroke. Brain neuroimaging may demonstrate structural changes including, but not limited to, focal atrophy, infarcts, and tumor, that may not be identified on physical examination. Additional evaluation with cerebrospinal fluid assays or genetic testing should be considered in atypical dementia cases, such as age of onset under 65 years, rapid symptom onset, and/or impairment in multiple cognitive domains but not episodic memory. For treatment, patients benefit from non-pharmacologic approaches, including cognitively engaging activities such as reading, physical exercise such as walking, and socialization such as family gatherings. Pharmacologic approaches can provide modest symptomatic relief. For AD, this includes an acetylcholinesterase inhibitor such as donepezil for mild-to-severe dementia, and memantine (used alone or as an add-on therapy) for moderate-to-severe dementia. Rivastigmine is approved for the symptomatic treatment of Parkinson’s disease dementia. AD currently affects 5.8 million persons in the US, and is a common cause of dementia which is usually accompanied by other neuropathology. Causes of dementia can be diagnosed by medical history, cognitive and physical examination, laboratory testing, and brain imaging. Management should include both non-pharmacologic and pharmacologic approaches.
                Bookmark

                Author and article information

                Journal
                Chron Respir Dis
                Chron Respir Dis
                spcrd
                CRD
                Chronic Respiratory Disease
                SAGE Publications (Sage UK: London, England )
                1479-9723
                1479-9731
                15 December 2023
                Jan-Dec 2023
                : 20
                : 14799731231222282
                Affiliations
                [1 ]Department of Internal Medicine, Ringgold 65521, universityHallym University College of Medicine; , Seoul, Korea
                [2 ]Department of Internal Medicine, Dongguk University Gyeongju Hospital, universityDongguk University College of Medicine; , Gyeongju, Korea
                [3 ]Department of Statistics and Actuarial Science, Ringgold 35016, universitySoongsil University; , Seoul, Korea
                [4 ]Department of Neurology, Soonchunhyang University College of Medicine, Ringgold 37969, universitySoonchunhyang University; , Cheonan, Korea
                [5 ]Department of Internal Medicine, universityHanyang University College of Medicine; , Seoul, Korea
                Author notes
                [*]Hyun Lee, Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea. Email: namuhanayeyo@ 123456hanyang.ac.kr
                [*]Hayoung Choi, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeongdeungpo-gu, Seoul 07441, Korea. Email: hychoimd@ 123456gmail.com
                [*]

                These authors contributed equally as co-first authors.

                Data Availability Statement included at the end of the article

                Author information
                https://orcid.org/0000-0002-0410-8524
                https://orcid.org/0000-0003-2459-3448
                https://orcid.org/0000-0002-3746-4947
                https://orcid.org/0000-0003-4812-0653
                Article
                10.1177_14799731231222282
                10.1177/14799731231222282
                10725102
                38100725
                f7f575bd-0dfa-4250-997d-b0df6542a77e
                © The Author(s) 2023

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                : 18 July 2023
                : 22 November 2023
                : 5 December 2023
                Funding
                Funded by: Ministry of Education, FundRef https://doi.org/10.13039/501100002701;
                Award ID: 2021R1I1A3052416
                Categories
                Original Paper
                Custom metadata
                ts10
                January-December 2023

                Respiratory medicine
                bronchiectasis,dementia,epidemiology,alzheimer disease,vascular dementia
                Respiratory medicine
                bronchiectasis, dementia, epidemiology, alzheimer disease, vascular dementia

                Comments

                Comment on this article